(E)-3-(4-methyl-2,5,7-trioxabicyclo[2.2.2]octan-1-yl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (E)-3-(4-methyl-2,5,7-trioxabicyclo[2.2.2]octan-1-yl)prop-2-enoic acid
• 化学式: C₉H₁₂O₅
• 分子量: 200.19
• InChiKey: CNJSMMKHRYNCFL-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES
  申请人：Alkermes Pharma Ireland Limited

  公开号：EP3366668A1

  公开（公告）日：2018-08-29

  The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

  本发明提供了式 (I) 化合物及其药物组合物。
• Prodrugs of fumarates and their use in treating various diseases
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10080733B2

  公开（公告）日：2018-09-25

  The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.

  本发明提供了式 (I) 化合物及其药物组合物。
• US20140275048A1
  申请人：——

  公开号：US20140275048A1

  公开（公告）日：2014-09-18
• PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20170095439A1

  公开（公告）日：2017-04-06

  The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
• Prodrugs of Fumarates and Their Use in Treating Various Diseases
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20200352893A1

  公开（公告）日：2020-11-12

  The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.